Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma-Reference-Cited by-同舟云学术

Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma

Published:2018-11-14 Issue:467 Volume:10 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Scafoglio Claudio R.¹^ORCID,Villegas Brendon¹^ORCID,Abdelhady Gihad¹^ORCID,Bailey Sean T.¹²^ORCID,Liu Jie³,Shirali Aditya S.⁴,Wallace W. Dean⁵,Magyar Clara E.⁵,Grogan Tristan R.⁶,Elashoff David⁶,Walser Tonya¹,Yanagawa Jane⁴,Aberle Denise R.⁷,Barrio Jorge R.³,Dubinett Steven M.¹³⁵⁸,Shackelford David B.¹

Affiliation:

1. Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.

2. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.

3. Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.

4. Division of Thoracic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.

5. Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.

6. Department of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.

7. Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.

8. Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA.

Abstract

Lung premalignancy and early-stage adenocarcinoma use a mechanism of glucose transport that can be targeted for early diagnosis and treatment.

Funder

American Cancer Society

Tobacco-Related Disease Research Program

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference55 articles.

1. Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer

2. Immune checkpoint inhibitors in advanced non-small cell lung cancer

3. Early lung cancer with lepidic pattern

4. Pulmonary adenocarcinoma: A renewed entity in 2011

5. Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fine mapping-based multi-omics analysis interprets the gut-lung axis function of SGLT2 inhibitors;Frontiers in Cellular and Infection Microbiology;2024-09-10

2. Plinabulin, a microtubule destabilising agent, in non-small-cell lung cancer: lessons from the DUBLIN-3 trial;The Lancet Respiratory Medicine;2024-09

3. Premalignant Progression in the Lung: Knowledge Gaps and Novel Opportunities for Interception of Non–Small Cell Lung Cancer. An Official American Thoracic Society Research Statement;American Journal of Respiratory and Critical Care Medicine;2024-09-01

4. The 2023 American Association for Thoracic Surgery (AATS) Expert Consensus Document: Management of subsolid lung nodules;The Journal of Thoracic and Cardiovascular Surgery;2024-09

5. From Hyperinsulinemia to Cancer Progression: How Diminishing Glucose Storage Capacity Fuels Insulin Resistance;Aging and Cancer;2024-08-27